EUCTR2011-003487-75-IT进行中（未招募）1 期
Phase II trial on safety and activity of intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma.
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点目标入组 19 人开始时间: 2011年12月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histology of Burkitt's lymphoma according to the 2008 WHO classification. 2. HIV sero-positivity. 3. Age >/= 18 and Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. CNS parenchymal involvement [patients with meningeal dissemination (lymphomatous meningosis) are eligible]. 2. Absolute neutrophil count < 1.000 cells/mcL and platelets count < 75 × 1000000000/L (Burkitt unrelated). 3. Creatinine > 1,5 ULN (Burkitt unrelated). 4. SGOT and/or SGTP > 2,5 ULN (Burkitt unrelated). 5. Bilirubin > 2 ULN (Burkitt unrelated). 6. Severe psychiatric illness or any other clinical, social or psychological condition that could interfere with patient's adherence and compliance. 7. Significant cardiac disease or acute myocardial infarction in the last 12 months. 8. Severe active infection (HBV and/or HCV co-infection does not constitute exclusion criteria in this trial). 9. Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ITAffibody AB110
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ESAffibody AB110
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-DEAffibody AB20
招募中
不适用
Phase II trial on the effectiveness and safety of bariatric surgery for advanced obesityadvanced obesityJPRN-UMIN000034438Wakayama Medical University24
已完成
不适用
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myelomaMultiple MyelomaJPRN-UMIN000016265Sapporo Medical University Hospital30